Drug Trial News

RSS
Merck's Phase III study shows efficacy results of tafluprost to treat ocular hypertension

Merck's Phase III study shows efficacy results of tafluprost to treat ocular hypertension

3 May 2011
Diabetes cell implant company approved for Argentina clinical trial

Diabetes cell implant company approved for Argentina clinical trial

3 May 2011
Positive Ellex 2RT data demonstrates efficacy in treatment of early Age-Related Macular Degeneration

Positive Ellex 2RT data demonstrates efficacy in treatment of early Age-Related Macular Degeneration

2 May 2011
Pearl's PT003 Phase 2b study results in COPD to be presented at ATS meeting

Pearl's PT003 Phase 2b study results in COPD to be presented at ATS meeting

30 Apr 2011
CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

30 Apr 2011
Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

29 Apr 2011
MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

29 Apr 2011
Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

29 Apr 2011
CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

28 Apr 2011
FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

28 Apr 2011
Curis reports first quarter net loss of $6.8 million

Curis reports first quarter net loss of $6.8 million

28 Apr 2011
Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

28 Apr 2011
Positive results from Shire's Vyvanse clinical trial in schizophrenia

Positive results from Shire's Vyvanse clinical trial in schizophrenia

28 Apr 2011
Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million

Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million

From Novo Nordisk 28 Apr 2011
Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME

Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME

28 Apr 2011
The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

28 Apr 2011
Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

28 Apr 2011
FDA Advisory Committee recommends approval of Merck's VICTRELIS for chronic HCV genotype 1 infection

FDA Advisory Committee recommends approval of Merck's VICTRELIS for chronic HCV genotype 1 infection

28 Apr 2011
CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

27 Apr 2011
Children, adolescents with liver disease may not benefit from vitamin E or metformin

Children, adolescents with liver disease may not benefit from vitamin E or metformin

27 Apr 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback